Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. - Wikidata - awgldk - TriplyDB

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

http://www.wikidata.org/entity/Q44381567

about

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials Abiraterone in metastatic prostate cancer without previous chemotherapy Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines The project data sphere initiative: accelerating cancer research by sharing data Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Circulating Tumor Cell Isolation and Analysis.Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data.Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests.Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.A perspective on protein profiling of blood.Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis.Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.Automated analysis of co-localized protein expression in histologic sections of prostate cancer.Is cancer vaccination feasible at older age?Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.Emerging treatment options for patients with castration-resistant prostate cancer.Strategies for cancer vaccine development.Vaccines as monotherapy and in combination therapy for prostate cancer.The importance of identifying and validating prognostic factors in oncology.Critical review of prostate cancer predictive tools Circulating tumor cells as biomarkers in prostate cancer.A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

P2860

Q24599547-7CBC2875-5A89-45C3-86C0-66490A2A3D35 Q24612084-172356AD-953C-417E-AC9E-04573FD408FC Q24630999-C9CDFA2E-607F-4F2F-A4D0-FD6E5EC5618D Q24632187-5ECD53DB-82A5-4F6F-8634-EEF06DE78145 Q26773406-6B9427D1-80D7-42E9-88CA-23DFE5FBC2EB Q26801000-C7793EA4-C76A-4DF2-A1E1-02297773AB57 Q26825512-ABDF7C46-4DAF-45B3-AE47-19361801766E Q27008070-452E9FBC-8788-47AD-9194-0EF6E2162624 Q28647805-B7631C24-8A69-4007-93C1-72D69D0AF280 Q30277291-758B9B40-2E80-4441-BBDF-C51EF8AA9E7D Q30358229-3BBE7201-9492-48BC-948A-CBC94AB29A1B Q30490354-0A1530C3-D1F9-420C-A646-9046975B61B8 Q30568800-F1FE495C-4B6A-4617-B918-BD31FE8A02F3 Q30827122-E3CDDD23-B269-4E2C-A6AE-1D90D13FE7C3 Q30835493-157BD543-31D2-40A4-9F46-4C974195C43E Q31123601-DF59ECAC-CA70-47C0-A85C-E86C6414D304 Q33221829-BEA5079D-421A-4823-909A-254D5EE7AF10 Q33390088-C56554DC-9C81-4661-B869-A1E24F45EAFB Q33391749-EC27EE88-2F63-41C2-8433-FF753B0F28D1 Q33408024-24072679-8EE4-47D5-B428-F4EA8489C245 Q33408667-36618F9F-F1F5-4E1C-BF96-A058457A0FA6 Q33410060-A05734FA-5019-40D0-A68F-945C2CE8354E Q33566395-468A0FE1-5461-4011-B395-C76D726B12BA Q33608134-FD9F5025-B305-4231-9A5F-27238312727E Q33613644-80ACC62C-B681-46FE-8836-3660C85B009F Q33621452-3C8E57B9-2C02-4A7B-8268-DEA12E4077EF Q33701534-291684EE-BC52-438A-A816-D15B9C1516F5 Q33703387-E0569CEA-EB2C-49AD-9C1C-1713F73B5726 Q33732080-B763FD3F-12E4-46CA-9697-4F9585841FBB Q33739907-3F5F2D69-7D0C-41DC-A1AF-2A887B6D9F00 Q33777534-FFD8E856-7C29-48A9-9FFE-B30A1745C336 Q33813626-3A6EDD22-E0F0-4328-AE17-3E8FD5BBBB90 Q33949736-4B9224D4-0B04-496C-BBA3-659CDF1044B3 Q33958519-D9DD9113-871E-4847-A825-39C05DE5B33A Q34038338-A0D79DC4-D292-486D-B382-70EEB0AED9E0 Q34039068-C52B577C-D75B-446F-B7F5-53DF0D7D5130 Q34090548-06DCDF76-62D1-46A3-8C55-7B33A42D1003 Q34104562-6D525F3F-3CF3-4576-BFFA-9E72586BC4DC Q34193303-62B7C533-9471-4196-BADF-4E0C34F71124 Q34289239-B91B345E-F49A-482C-A823-8A53BC965482

P2860

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

http://www.wikidata.org/entity/Q44381567

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Prognostic model for predictin ...... ry metastatic prostate cancer.

@en

Prognostic model for predictin ...... ry metastatic prostate cancer.

@nl

type

label

Prognostic model for predictin ...... ry metastatic prostate cancer.

@en

Prognostic model for predictin ...... ry metastatic prostate cancer.

@nl

prefLabel

Prognostic model for predictin ...... ry metastatic prostate cancer.

@en

Prognostic model for predictin ...... ry metastatic prostate cancer.

@nl

P1433

Q44381567-3F1535D9-769A-4A0A-992D-50B3A096DABF

P1476

Q44381567-6850B82C-FD93-45FD-99CD-071AB28A5D10

P2093

Q44381567-770B8E67-5A93-4B81-9D7E-7B22EF3B2071

Q44381567-87DFEAF7-A8A7-4716-90E5-5F964345DF30

Q44381567-BCDB55BE-18FD-4246-8EEA-513AC4397AC4

Q44381567-C54884E6-566F-4EDE-BB02-EF709EF595FC

Q44381567-D2C80022-007E-49B9-B626-5AC672E5A197

Q44381567-D90378AC-8407-4E6B-926E-7D4DC9D68762

Q44381567-E86C4DC6-7769-4517-B9E5-A60DE741F75B

P304

Q44381567-3FA7DA0F-B088-40E0-A58F-8FF216361F17

P31

Q44381567-5351B957-4D90-4A68-ADD9-F9CCDAA096B8

P356

Q44381567-92F9FE13-8C54-4B0F-954B-9F83EAD377A9

P407

Q44381567-FE7C7CD8-5B8E-4C4D-8123-B8EF2DB44890

P433

Q44381567-31D07050-675F-4B9D-860A-4F58686B1A1C

P478

Q44381567-413D5E53-87B6-4033-9D5D-A9B7B72C3DBA

P50

Q44381567-077DF698-1C3B-4E8A-8958-D88BC87255FC

Q44381567-A70A2E5A-4A89-4940-B88C-B9CEC7C17655

P577

Q44381567-814268B7-24AD-4AB9-B88B-DB1E90174684

P698

Q44381567-9E77B1C7-B7C3-479B-9D3C-6BB1407F9492

P356

JCO.2003.06.100

P1433

Journal of Clinical Oncology

P1476

Prognostic model for predictin ...... ory metastatic prostate cancer

@en

P2093

Brent A Blumenstein

http://www.w3.org/2001/XMLSchema#string

Ellen B Kaplan

http://www.w3.org/2001/XMLSchema#string

Ellis G Levine

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

Michael W Kattan

http://www.w3.org/2001/XMLSchema#string

Nancy A Dawson

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

P304

1232-1237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.06.100

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12663709

http://www.w3.org/2001/XMLSchema#string